{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:20Z","timestamp":1793323340353,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This study aimed to evaluate and compare the efficacy and safety of romosozumab vs denosumab in hemodialysis (HD) patients with osteoporosis. A 12-mo observational study was conducted involving HD patients with osteoporosis at a single dialysis center. The study compared outcomes between 2 treatment groups: romosozumab (210\u00a0mg monthly, n\u2009=\u200921) and denosumab (60\u00a0mg every 6 mo, n\u2009=\u200924). Treatment allocation was based on cardiovascular history. Changes in bone mineral density (BMD), bone turnover markers (P1NP, TRACP-5b, and intact PTH), complications, and fractures were assessed. Serum calcium levels were monitored weekly. After 12 mo, patients receiving romosozumab showed significantly greater improvements in lumbar spine (LS) BMD compared to denosumab (14.6% vs 6.3%, p\u2009&amp;lt;\u2009.05). Both treatments demonstrated comparable increases in femoral neck (FN) BMD (4.3% vs 6.0%, p\u2009=\u2009.41). Bone turnover markers showed distinct patterns between groups, with romosozumab producing more pronounced early effects. P1NP levels increased significantly in the romosozumab group at 6 mo (+41.2%) before declining toward baseline, while showing sustained suppression in the denosumab group. The incidence of osteoporotic fractures was one case per group (vertebral fracture in romosozumab group, hip fracture in denosumab group). One case of injection site reactions was observed in the romosozumab group. Mean serum calcium levels remained stable in both groups throughout the study period. The treatment of romosozumab appears to be more effective than denosumab for improving BMD in HD patients with osteoporosis, particularly at the LS. Both treatment approaches demonstrated acceptable safety profiles, though careful monitoring of calcium levels and cardiovascular status is recommended.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf096","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T08:07:31Z","timestamp":1749024451000},"source":"Crossref","is-referenced-by-count":7,"title":["Comparative analysis of romosozumab and denosumab treatment in hemodialysis patients with osteoporosis: a 12-mo observational study"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4578-0656","authenticated-orcid":false,"given":"Masatoshi","family":"Teraguchi","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Wakayama Medical University , Wakayama 641-8509 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorihide","family":"Kitayama","sequence":"additional","affiliation":[{"name":"Chuki Clinic , Wakayama 649-1342 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Chuki Clinic , Wakayama 649-1342 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zyun","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Chuki Clinic , Wakayama 649-1342 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Chuki Clinic , Wakayama 649-1342 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Wakayama Medical University , Wakayama 641-8509 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"Suppl 113","key":"2025071511064869600_ref1","first-page":"S1","article-title":"KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","year":"2009","journal-title":"Kidney Int"},{"issue":"1","key":"2025071511064869600_ref2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int"},{"issue":"6","key":"2025071511064869600_ref3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00774-020-01149-3","article-title":"Executive summary of clinical practice guide on fracture risk in lifestyle diseases","volume":"38","author":"Kanazawa","year":"2020","journal-title":"J Bone Miner Metab"},{"issue":"11","key":"2025071511064869600_ref4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"issue":"1","key":"2025071511064869600_ref5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"issue":"8","key":"2025071511064869600_ref6","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2025071511064869600_ref7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther Apher Dial"},{"issue":"2","key":"2025071511064869600_ref8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1053\/j.ajkd.2013.12.018","article-title":"Bone disease in CKD: a focus on osteoporosis diagnosis and management","volume":"64","author":"Miller","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"2025071511064869600_ref9","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s00198-021-05975-7","article-title":"Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism","volume":"32","author":"Evenepoel","year":"2021","journal-title":"Osteoporos Int"},{"key":"2025071511064869600_ref10","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials","volume":"29(12)","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025071511064869600_ref11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025071511064869600_ref12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","article-title":"Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies","volume":"29","author":"Thongprayoon","year":"2017","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025071511064869600_ref13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"Kneissel M.WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2025071511064869600_ref14","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","article-title":"Sclerostin and Dickkopf-1 in renal osteodystrophy","volume":"6","author":"Cejka","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"2025071511064869600_ref15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"2025071511064869600_ref16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2025071511064869600_ref17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ndt\/gfy129","article-title":"Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!","volume":"34","author":"Brandenburg","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2025071511064869600_ref18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2025071511064869600_ref19","doi-asserted-by":"publisher","first-page":"ziae137","DOI":"10.1093\/jbmrpl\/ziae137","article-title":"Romosozumab versus bisphosphonates for preventing subsequent vertebral fractures after balloon kyphoplasty: comparison using data from two prospective multicenter studies","volume":"9","author":"Inose","year":"2024","journal-title":"JBMR Plus"},{"issue":"6","key":"2025071511064869600_ref20","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized controlled trial","volume":"34","author":"Iseri","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2025071511064869600_ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2372","volume":"99","author":"Ishimura","journal-title":"J clin Endocrinol Metab"},{"key":"2025071511064869600_ref22","volume":"20","author":"Kuo","journal-title":"BMC Nephrol"},{"issue":"4","key":"2025071511064869600_ref23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA osteoporosis study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf096\/63434315\/ziaf096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/8\/ziaf096\/63434315\/ziaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/8\/ziaf096\/63434315\/ziaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:06:56Z","timestamp":1752592016000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf096\/8156589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf096","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,6,4]]},"article-number":"ziaf096"}}